Numerous invited lectures at national and international scientific symposia in the fields of CNS disorders, drug abuse and obesity. In addition, more than 500 communications have been given as oral presentations and posters at scientific symposia. Please contact us for further information about any of these talks.
Safety Pharmacology Society Virtual Meeting, 4th-8th October 2021.
Talk entitled "Psychedelics and CNS Drugs with Novel Mechanisms. Non-clinical Abuse Evaluations to Meet the Challenge". Part of the Continuing Education (CE) course "CNS Biomarkers of Mood Disorders and Drug Abuse: Where are We?" associated with the SPS Virtual Meeting, 11th October 2021.
DevelRx - Altasciences Joint Podcast, 21st September 2021.
Podcast entitled "The Next Trip - Developing the Second Generation of Psychedelics and their Analogs for Targeted Medical Use". In this podcast, experts from DevelRx and Altasciences examined the preclinical, clinical and regulatory challenges facing the development of more efficacious and safer psychedelic drugs.
College on Problems of Drug Dependence (CPDD), Workshop at the 83rd Annual Scientific Virtual Meeting, 21st-24th June, 2021.
Talk entitled: "Refinements and Innovations in Non-clinical Abuse Evaluations" in Workshop "Meeting the Challenge of the Psychedelics and CNS Drugs with Novel Mechanisms - Building on the Foundation of the FDA 2017 Guidance on the Assessment of Abuse Potential". 23rd June 2021.
Psychedelic Therapeutics and Drug Development Conference, 4th-6th May 2021.
Talk entitled: “How non-clinical research can inform the clinical development and prescribing of psychedelic drugs.”
British Pharmacological Society (BPS), Laboratory Animal Science Association (LASA) and Psychiatry Consortium joint workshop, February 2021.
Talk entitled: “Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation.”
Dutch Paediatric Society (NVK; Nederlandse Vereniging voor Kindergeneeskunde) Virtual Meeting, December 2020.
At the invitation of Takeda Pharmaceuticals, DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder. Talk entitled: “How can Pharmacology Help Determine Treatment Choice in ADHD?”
American College of Toxicology (ACT) Virtual Meeting, November 2020.
Talk entitled: “Understanding the Assessment of Abuse Potential: An Industry and Regulatory Perspective.” Continuing Education Course.
Shire Psychiatry Educational Forum, 2019.
Talk entitled: “A place for amphetamines in clinical practice.”
College on Problems of Drug Dependence (CPDD) Workshop at the 80th Annual Meeting, 2018.
Talk entitled: “An evaluation of the discriminative and reinforcing properties of cannabidiol in rats." In Workshop "Therapeutic Applications and Abuse Liability Assessment of Cannabidiol".
Shire Symposium at the Eunethydis International Conference, 2018.
Making it Happen: ADHD Guidelines in Clinical Practice.
Talk entitled: “How can pharmacology help determine treatment choice in ADHD?”
Pinney Associates – RenaSci Supported International Webex, 2018.
Developing Psychedelics into Medicine: Potential and Pitfalls. Talk entitled: “Developing psychedelic drugs for medical use - dealing with the regulatory challenge of non-clinical abuse and dependence assessments.”
Cross Company Abuse Liability Council (C-CALC), 2018.
Advancements and Challenges in Abuse Potential Evaluation. Talk entitled: “An evidence-based evaluation of the possible influence of gender on results from drug-discrimination, intravenous self-administration and tolerance / dependence safety pharmacology testing.”
AddRess - Center for Addiction Research & Science, 2018.
Talk entitled: “Developing psychedelic drugs for medical use – regulatory challenges.”